Novotech has agreed to acquire Agilex Biolabs, adding specialist bioanalytical laboratory capabilities to its Australian clinical-development platform. Agilex provides bioanalytical services supporting early-stage drug development and will broaden Novotech's ability to offer integrated laboratory and clinical services. The acquisition strengthens Novotech's early-phase infrastructure in Australia and expands the range of services available to biotechnology and pharmaceutical sponsors. Field Content Article Type Deals Companies Novotech; Agilex Biolabs Deal Type Acquisition Acquired Company Agilex Biolabs Sector Contract research organisation and bioanalytical services Capabilities Bioanalysis; early-phase drug development support; laboratory services Geography Australia What Happened Novotech agreed to acquire Adelaide-based Agilex Biolabs. Why It Matters The transaction adds specialist bioanalytical laboratory capabilities to Novotech's existing clinical-development infrastructure. Supporting Context Agilex supports pharmaceutical and biotechnology clients with bioanalytical services used during early drug development. Strategic Rationale The acquisition enables Novotech to provide a more integrated clinical and laboratory offering to sponsors. Potential Impact Clients may be able to consolidate more early-phase clinical and bioanalytical work within a single service provider. Key Takeaway Novotech is expanding its Australian early-development platform through the acquisition of Agilex Biolabs. What to Watch Transaction completion, integration of Agilex capabilities and expansion of combined laboratory services. Primary Source Novotech Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates. The initial assets are SB41, a proposed biosimilar to Fasenra, and SB44, a proposed biosimilar to Ilaris, with Samsung Bioepis leading development and manufacturing. Teva will contribute commercial capabilities across the US, Europe and Canada, creating a multi-product platform spanning major immunology and inflammatory-disease markets. Field Content Article Type Deals Companies Samsung Bioepis; Teva Pharmaceuticals Deal Type Strategic biosimilars development and commercialisation partnership Initial Assets SB41; SB44 Reference Products Fasenra; Ilaris Programme Scope Two named biosimilars plus options for up to four additional candidates Therapy Areas Immunology; inflammatory disease Technology/Modality Monoclonal antibody biosimilars Development Responsibilities Samsung Bioepis will lead development, regulatory activities and manufacturing Commercial Responsibilities Teva will contribute commercial infrastructure in agreed markets Core Markets United States; Europe; Canada What Happened Samsung Bioepis and Teva expanded their strategic partnership to cover up to six potential biosimilar candidates. Why It Matters The agreement creates a sizeable multi-asset biosimilars collaboration spanning major biologic markets and multiple geographies. Strategic Rationale Samsung Bioepis contributes biosimilar development and manufacturing expertise while Teva provides established commercial infrastructure. Potential Impact The partnership could increase biosimilar competition across high-value immunology and inflammatory-disease products. Key Takeaway Samsung Bioepis and Teva are building a biosimilars portfolio of up to six candidates, starting with proposed Fasenra and Ilaris biosimilars. What to Watch Regulatory development of SB41 and SB44 and selection of the four optional additional candidates. Primary Source Samsung Bioepis Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront and could earn up to $7 billion in additional development, regulatory and commercial milestone payments. The expanded partnership includes long-acting IL-13 and IL-4/IL-13 programmes and retains an equal sharing model for development costs, commercialisation costs and future profits. Field Content Article Type Deals Companies Sanofi; Regeneron Deal Type Expanded global immunology research and development alliance Therapy Area Immunology Programme Scope Four next-generation long-acting antibody programmes Key Assets REGN20423; long-acting IL-4xIL-13 bispecific and additional antibody programmes Technology/Modality Monoclonal and bispecific antibodies Upfront Payment $1 billion Potential Milestones Up to $7 billion Potential Deal Value Up to $8 billion Economics Development and commercialisation costs and future profits shared equally What Happened Sanofi and Regeneron expanded their longstanding immunology alliance to include four next-generation antibody programmes. Why It Matters The transaction extends one of biopharma's most established immunology partnerships into additional long-acting programmes intended to build on the companies' experience with Dupixent. Strategic Rationale Sanofi and Regeneron are combining their immunology development capabilities to create longer-acting and potentially differentiated therapies across inflammatory diseases. Potential Impact Successful programmes could expand the companies' presence across major immunology indications and create successors or complements to existing therapies. Key Takeaway Sanofi and Regeneron have expanded their immunology alliance in a transaction worth up to $8 billion. What to Watch Clinical progression of REGN20423, development of the IL-4xIL-13 bispecific and disclosure of the remaining programmes. Primary Source Regeneron Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved the first surgically implanted heart valve designed to be enlarged as a child grows, potentially reducing the need for repeat operations. The Autus Size-Adjustable Valve is approved for paediatric patients with congenital pulmonary valve disease and can be expanded later using a balloon catheter. It is also the first US-approved heart valve to use polymeric rather than animal-derived leaflets, introducing a new approach to long-term paediatric valve replacement. Field Content Article Type Approvals Product Autus Size-Adjustable Valve Regulatory Authority U.S. Food and Drug Administration Approval Type Medical device approval Indication Paediatric patients with congenital pulmonary valve disease requiring surgical pulmonary valve replacement Patient Population Children with congenital pulmonary valve disease Therapy Area Cardiology; congenital heart disease; paediatric cardiology Technology/Modality Size-adjustable surgically implanted pulmonary heart valve Valve Material Polymeric leaflets Geography United States What Happened The FDA approved the Autus Size-Adjustable Valve for paediatric pulmonary valve replacement. Why It Matters The valve can be enlarged using a balloon catheter as a child grows, potentially reducing the need for repeated open-heart surgery. Supporting Context The device is also the first US-approved heart valve to use polymeric rather than animal-derived leaflets. Potential Impact The technology may reduce lifetime surgical burden for children who would otherwise outgrow fixed-size replacement valves. Key Takeaway The Autus valve is the first FDA-approved heart valve designed to grow with paediatric patients. What to Watch Clinical adoption, long-term durability and real-world evidence on avoidance of repeat surgery. Primary Source U.S. Food and Drug Administration Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

SpyGlass Pharma has acquired Advanced Vision Science for approximately $13 million, bringing manufacturing of a key intraocular lens used in its drug-delivery platform in-house. The acquired business manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, which is being developed as a sustained ophthalmic drug-delivery platform. The acquisition gives SpyGlass direct control over an important manufacturing capability as it prepares for potential commercialisation and future expansion of the platform. Field Content Article Type Deals Companies SpyGlass Pharma; Advanced Vision Science; Santen Deal Type Acquisition Transaction Value Approximately $13 million in cash Acquired Company Advanced Vision Science Therapy Area Ophthalmology Technology/Modality Intraocular lens manufacturing and sustained ophthalmic drug delivery Key Programme BIM-IOL System Development Stage Phase III What Happened SpyGlass Pharma acquired 100% of Advanced Vision Science from Santen for approximately $13 million in cash. Why It Matters Advanced Vision Science manufactures the intraocular lens used in SpyGlass' Phase III BIM-IOL System, making the acquisition strategically important to future supply and commercialisation. Strategic Rationale Owning the manufacturing capability gives SpyGlass greater control over production, scale-up and potential commercial supply. Potential Impact The transaction could reduce supply-chain dependence and support expansion of SpyGlass' ophthalmic drug-delivery platform. Key Takeaway SpyGlass has acquired a critical intraocular-lens manufacturing business supporting its Phase III ophthalmology platform. What to Watch Integration of AVS, Phase III progress for BIM-IOL and commercial manufacturing scale-up. Primary Source SpyGlass Pharma Relevant Date 1 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Medscape's 2026 Canada physician compensation report shows average total physician compensation of C$394,000, while fewer than half of respondents say they feel fairly paid. Average base salary was reported at C$290,000, with the survey also highlighting unpaid work and continuing financial pressure across the Canadian medical workforce. The findings provide a current benchmark for physician earnings, perceived compensation fairness and the wider economics affecting medical practice in Canada. Field Content Article Type Compensation Report Medscape Canada Physician Compensation Report 2026 Geography Canada Average Total Compensation C$394,000 Average Base Salary C$290,000 Fairly Compensated 47% of respondents Topic Physician compensation and workforce economics What Happened Medscape published its 2026 Canadian physician compensation report with new data on earnings and perceptions of pay. Why It Matters The report provides a current benchmark for physician remuneration while highlighting ongoing dissatisfaction with compensation and the burden of unpaid work. Supporting Context Less than half of surveyed physicians said they felt fairly compensated despite average total compensation approaching C$400,000. Workforce Context The findings sit within broader concerns around physician workload, practice costs and recruitment and retention pressures. Potential Impact Compensation trends can influence specialty choice, workforce mobility, recruitment and long-term health-system staffing. Key Takeaway Canadian physicians reported average total compensation of C$394,000, but only 47% said they felt fairly compensated. What to Watch Specialty-level pay differences, gender gaps, changes in unpaid workload and future compensation trends. Primary Source Medscape Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novo Nordisk has licensed Hengrui Pharma's once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 in a global deal worth up to $2.6 billion. Hengrui will receive $300 million upfront, while Novo Nordisk gains exclusive rights outside Greater China to the Phase I-ready metabolic-disease candidate. The agreement adds another oral incretin programme to Novo Nordisk's pipeline as competition intensifies across obesity and diabetes treatment. Field Content Article Type Deals Companies Novo Nordisk; Hengrui Pharma Deal Type Exclusive global licensing agreement Asset HRS-1596 Therapy Areas Obesity; type 2 diabetes; metabolic disease Technology/Modality Once-weekly oral GLP-1/GIP dual receptor agonist Development Stage Phase I-ready Upfront Payment $300 million Potential Deal Value Up to $2.6 billion Additional Economics Sales royalties Geography Worldwide excluding Greater China What Happened Novo Nordisk secured exclusive rights outside Greater China to Hengrui Pharma's HRS-1596. Why It Matters The transaction adds a once-weekly oral incretin candidate to Novo Nordisk's metabolic pipeline as competition grows around more convenient obesity and diabetes therapies. Supporting Context HRS-1596 is designed as an oral dual agonist of the GLP-1 and GIP receptors. Strategic Rationale Novo Nordisk gains another potential oral metabolic therapy while Hengrui receives substantial upfront funding and downstream milestone opportunities. Potential Impact Successful development could broaden treatment choice beyond injectable incretin medicines. Key Takeaway Novo Nordisk has licensed HRS-1596 in a deal worth up to $2.6 billion, including $300 million upfront. What to Watch Entry into clinical development, early safety and efficacy data and future positioning within Novo Nordisk's obesity and diabetes portfolio. Primary Source Novo Nordisk / Hengrui Pharma Relevant Date 29 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ALK is investing approximately DKK 500 million to expand its long-term manufacturing partnership with Catalent and increase capacity for fast-dissolving allergy immunotherapy tablets. The three-year investment programme is expected to add around 300 million tablets of annual capacity, taking potential production to approximately 1.1 billion tablets from the early 2030s. The expanded partnership also secures long-term access to Catalent's Zydis technology and could support future peanut and tree-nut allergy tablet programmes. Field Content Article Type Deals Companies ALK; Catalent Deal Type Strategic manufacturing partnership expansion Investment Approximately DKK 500 million over three years Technology/Platform Catalent Zydis fast-dissolving tablet technology Therapy Areas Allergy; immunotherapy Manufacturing Scope Allergy immunotherapy tablets Additional Annual Capacity Approximately 300 million tablets Expected Total Annual Capacity Approximately 1.1 billion tablets from the early 2030s Potential Future Programmes Peanut and tree-nut allergy tablets What Happened ALK expanded its manufacturing partnership with Catalent through a DKK 500 million investment programme. Why It Matters The agreement materially increases production capacity for ALK's tablet-based allergy immunotherapy portfolio and secures long-term access to a specialised drug-delivery platform. Supporting Context Catalent's Zydis technology is used for rapidly dissolving oral tablets and forms part of ALK's existing allergy tablet manufacturing network. Strategic Rationale ALK is expanding capacity ahead of anticipated long-term demand and potential launches in additional allergy indications. Potential Impact Higher capacity could support wider global access to allergy immunotherapy tablets and future expansion into food-allergy treatment. Key Takeaway ALK is committing around DKK 500 million to increase annual allergy-tablet capacity to approximately 1.1 billion units. What to Watch Capacity build-out, future product launches and development of peanut and tree-nut allergy tablets. Primary Source ALK Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. Gazyva (obinutuzumab) reduced relapse risk in the Phase III INShore study, with 95% of treated patients experiencing no relapse after week eight and remaining in complete remission at one year. The approval introduces a B-cell-targeted therapy into a paediatric and adult nephrology setting where repeated relapses and prolonged immunosuppression can create substantial treatment burden. Field Content Article Type Approvals Drug Name Obinutuzumab Brand Name Gazyva Company Roche / Genentech Regulatory Authority U.S. Food and Drug Administration Approval Type New indication approval Indication Frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in patients in complete remission Patient Population Adults and children aged two years and older Therapy Areas Nephrology; rare disease; paediatrics Technology/Modality Anti-CD20 monoclonal antibody Clinical Study Phase III INShore Key Result 95% of Gazyva-treated patients experienced no relapse after week eight and were in complete remission at one year, compared with 73% receiving mycophenolate mofetil Geography United States What Happened The FDA approved Gazyva to reduce relapse risk in eligible patients with childhood-onset idiopathic nephrotic syndrome. Why It Matters The approval provides a new B-cell-directed option for patients with frequently relapsing or steroid-dependent disease. Supporting Context Relapsing nephrotic syndrome can require repeated corticosteroid or immunosuppressive treatment, creating significant long-term treatment burden. Potential Impact Gazyva may help prolong remission and reduce relapse frequency in eligible patients. Key Takeaway Gazyva is now FDA approved for frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome from age two. What to Watch Treatment uptake, durability of remission and positioning relative to existing immunosuppressive strategies. Primary Source U.S. Food and Drug Administration Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has expanded Camzyos approval to paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy who weigh at least 30kg. Camzyos (mavacamten) is now approved to improve functional capacity and symptoms in both adults and eligible paediatric patients with obstructive hypertrophic cardiomyopathy. The expansion, supported by the Phase III SCOUT-HCM study, extends cardiac myosin inhibition into a younger patient population with this inherited heart condition. Field Content Article Type Approvals Drug Name Mavacamten Brand Name Camzyos Company Bristol Myers Squibb Regulatory Authority U.S. Food and Drug Administration Approval Type Indication expansion Indication Symptomatic obstructive hypertrophic cardiomyopathy Patient Population Adults and paediatric patients weighing at least 30kg Therapy Areas Cardiology; hypertrophic cardiomyopathy Technology/Modality Cardiac myosin inhibitor Clinical Study Phase III SCOUT-HCM Geography United States What Happened The FDA expanded Camzyos approval to eligible paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. Why It Matters The decision extends a disease-specific therapy for oHCM into a paediatric population with limited targeted treatment options. Supporting Context Bristol Myers Squibb describes Camzyos as the only FDA-approved therapy for oHCM in a paediatric population. Potential Impact The label expansion broadens access to cardiac myosin inhibition for younger patients meeting the weight and disease criteria. Key Takeaway Camzyos is now FDA approved for symptomatic oHCM in adults and eligible paediatric patients. What to Watch Paediatric uptake, guideline integration and longer-term safety and effectiveness data from younger patients. Primary Source Bristol Myers Squibb Relevant Date 30 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

AstraZeneca is investing $2 billion in Summit Therapeutics while launching a clinical collaboration centred on the PD-1/VEGF bispecific antibody ivonescimab. The investment gives AstraZeneca an interest equivalent to approximately 12% of Summit's outstanding common stock and establishes an initial programme combining ivonescimab with AstraZeneca's CLDN18.2 ADC sonesitatug vedotin. The collaboration creates a broader framework for testing ivonescimab alongside additional AstraZeneca oncology medicines across gastrointestinal and potentially other cancers. Field Content Article Type Deals Companies AstraZeneca; Summit Therapeutics Deal Type Strategic equity investment and clinical collaboration Investment $2 billion Equity Position Equivalent to approximately 12% of Summit Therapeutics' outstanding common stock Key Asset Ivonescimab Therapy Areas Oncology; gastrointestinal cancers Technology/Modality PD-1/VEGF bispecific antibody Initial Combination Ivonescimab plus sonesitatug vedotin Partner Asset Sonesitatug vedotin, a CLDN18.2 antibody-drug conjugate What Happened AstraZeneca agreed a $2 billion investment in Summit Therapeutics alongside a clinical collaboration around ivonescimab. Why It Matters The transaction pairs a late-stage bispecific immunotherapy platform with AstraZeneca's broad oncology pipeline and creates opportunities for multiple combination strategies. Supporting Context The first announced programme will evaluate ivonescimab with AstraZeneca's CLDN18.2 ADC in gastrointestinal cancers. Strategic Rationale AstraZeneca gains exposure to ivonescimab while Summit gains a major pharmaceutical partner for combination development. Potential Impact The partnership could expand the range of ivonescimab combinations evaluated across solid tumours. Key Takeaway AstraZeneca is investing $2 billion in Summit and building a wider oncology collaboration around ivonescimab. What to Watch Clinical trial initiation, additional combination programmes and development strategy across tumour types. Primary Source AstraZeneca Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sun Pharma has secured rights to commercialise and manufacture LIB Therapeutics' PCSK9 inhibitor lerodalcibep across markets outside the US and China. The agreement covers the EU-approved therapy, marketed as Lyrokaul, and includes upfront and milestone payments to LIB Therapeutics as well as royalties on future sales. The partnership expands Sun Pharma's cardiovascular portfolio while providing LIB Therapeutics with a commercialisation partner across a broad international territory. Field Content Alert Type Licensing agreement Companies Sun Pharmaceutical Industries; LIB Therapeutics Deal Type Exclusive licensing, commercialisation and manufacturing agreement Asset or Company Lerodalcibep (Lyrokaul) Therapy Area(s) Cardiovascular disease; hypercholesterolaemia Technology or Modality PCSK9 inhibitor Deal Value Upfront and milestone payments plus royalties; financial amounts not disclosed Development Stage Approved in the European Union Geography Markets outside the US and China What Happened Sun Pharma entered an agreement with LIB Therapeutics for the licensing, commercialisation and manufacturing of lerodalcibep outside the US and China. Why It Matters The transaction gives Sun Pharma access to an approved PCSK9-targeted cardiovascular therapy across a broad international territory. Supporting Context Lerodalcibep, marketed as Lyrokaul, has received European Union approval for the treatment of adults with primary hypercholesterolaemia and mixed dyslipidaemia. Strategic Rationale The agreement expands Sun Pharma's specialty cardiovascular portfolio while providing LIB Therapeutics with commercial and manufacturing capabilities across international markets. Potential Impact The partnership could broaden commercial access to lerodalcibep across markets covered by the agreement. Key Takeaway Sun Pharma has secured broad ex-US and ex-China rights to LIB Therapeutics' approved PCSK9 inhibitor lerodalcibep. What to Watch Commercial rollout of lerodalcibep in markets covered by the agreement and any subsequent regulatory or reimbursement developments. Primary Source Sun Pharmaceutical Industries Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com